Zymeworks (ZYME) announced the U.S. FDA has cleared the investigational new drug application for ZW251, a novel glypican-3-targeted ADC incorporating the company’s proprietary topoisomerase 1 inhibitor payload, ZD06519, for the treatment of HCC. The company plans to commence Phase 1 clinical studies for ZW251 in 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks to Announce Q2 2025 Financials and Engage in Investor Conferences
- Positive Buy Rating for Zymeworks Amid Promising Clinical Trials and Strategic Partnerships
- Zymeworks: Hold Rating Amid Uncertain Market Potential and Upcoming Catalysts
- Zymeworks Gains Momentum with European Approval and Promising Financial Milestones for Zanidatamab
- Zymeworks Amends Warrant Agreement with EcoR1 Capital